<DOC>
	<DOCNO>NCT00774267</DOCNO>
	<brief_summary>The objective study evaluate quantitative change mammographic breast density baseline 24 month postmenopausal woman receive daily dos either BZA 20 mg/CE 0.45 mg , BZA 20 mg/CE 0.625 mg , Raloxifene placebo . The primary endpoint study change mammographic breast density baseline month 24 group .</brief_summary>
	<brief_title>Study Evaluating Changes In Mammographic Breast Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Subjects complete scheduled evaluation protocol 3115A1303WW . Completed 24 month treatment protocol 3115A1303 . Had mammogram baseline visit month 24 visit protocol 3115A1303 , original film technically acceptable reading . Was least 80 % compliant test article administration protocol 3115A1303 . Had mammogram either baseline month 24 3115A1303 study technically unsatisfactory . One mammogram digitize obtain 3115A1303 study . Had one mammogram either baseline month 24 visit study 3115A1303 .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>